1	Antimicrobial susceptibility and risk factors for resistance among <i>Escherichia coli</i> isolated
2	from canine specimens submitted to a diagnostic laboratory in Indiana, 2010-2019
3	
4	Short title: AMR in <i>E. coli</i> isolated from specimens collected from dogs
5	
6	John E. Ekakoro <sup>1</sup> , G. Kenitra Hendrix <sup>2</sup> , Lynn F. Guptill <sup>3</sup> , and Audrey Ruple <sup>4*</sup>
7	<sup>1</sup> Department of Public and Ecosystem Health, College of Veterinary Medicine, Cornell
8	University, Ithaca, NY, United States of America.
9	<sup>2</sup> Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University,
10	West Lafayette, IN, United States of America.
11	<sup>3</sup> Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue
12	University, West Lafayette, IN, United States of America.
13	<sup>4</sup> Department of Population Health Sciences, Virginia-Maryland College of Veterinary Medicine,
14	Virginia Tech, Blacksburg, VA, United States of America.
15	*Corresponding author: aruple@vt.edu
16	
17	Key words
18	Antimicrobial resistance, Escherichia coli, dogs, multivariable logistic regression.
19	
20	

# 21 Abstract

22 Escherichia coli (E. coli) is the most common Gram-negative pathogen isolated in human 23 infections. Antimicrobial resistant (AMR) E. coli originating from dogs may directly or 24 indirectly cause disease in humans. The objective of this study was to calculate the proportion of antimicrobial susceptible E. coli isolated from canine specimens submitted to the Indiana Animal 25 26 Disease Diagnostic Laboratory and to identify temporal patterns of susceptibility among these isolates. Susceptibility data of 2,738 E. coli isolates from dogs from 2010 through 2019 were 27 28 used in this study. Proportions of isolates susceptible to the various antimicrobials were 29 calculated using SAS statistical software and the Cochran-Armitage trend test was used to investigate the temporal trends in susceptibility. A multivariable binary logistic regression model 30 was built to investigate the association between host factors and AMR. Overall, 553/2,738 31 (20.2%) of the isolates were susceptible to 17 of the 27 antimicrobials examined. Of the 2,638 32 isolates examined for amikacin susceptibility, 2,706 (97.5%) were susceptible, 2,657/2,673 33 (99.4%) isolates were susceptible to imipenem, and 2,099/2,670 (78.6%) were susceptible to 34 marbofloxacin. A significant decreasing trend in susceptibility was observed for amoxicillin-35 clavulanic acid (P<0.0001), ampicillin (P<0.0001), Cefazolin (P<0.0001), ceftazidime 36 37 (P=0.0067), chloramphenicol (P<0.0001), and orbifloxacin (P=0.008). The overall percentage of AMR isolates (isolates not susceptible to at least one antimicrobial) was 61.7% (1,690/2,738) 38 39 and 29.3 % (801/2,738) of isolates were multidrug resistant. Multivariable regression analyses showed significant associations between AMR and age (P=0.0091), breed (P=0.0008), and 40 sample isolation site/source (P < 0.0001). The decreasing trend in the proportion of isolates 41 susceptible to several beta-lactam antimicrobials suggests that resistance of Escherichia coli in 42

dogs to these antimicrobials could be increasing in Indiana. The decreasing trend in susceptibilityto these drugs could be due to selection pressure from antimicrobial use.

45

# 46 Introduction

47 Escherichia coli, a member of the ESBL-producing Enterobacteriaceae, is the most 48 common Gram-negative pathogen isolated in human clinical infections, and antimicrobial 49 resistant (AMR) E. coli pose a threat to both human and animal health [1]. Previous studies have 50 reported isolation of transmissible AMR E. coli in dogs [2]. E. coli is the most common cause of urinary tract infections in humans and dogs and sharing of E. coli strains between dogs and 51 52 humans can occur [3]. The CDC reported that an estimated 197,400 cases of and 9,100 deaths 53 occured due to ESBL-Enterobacteriaceae infections among hospitalized patients in 2017 in the US [4]. AMR E. coli originating from dogs may directly or indirectly cause disease in humans 54 [5]. 55

However, we do not know the total number of cases in which AMR E. coli cause disease 56 or death in dogs in the US. Without this knowledge, we cannot fully understand the role dogs 57 may play in spreading AMR E. coli infections to humans. In addition, understanding the patterns 58 of antimicrobial susceptibility of bacterial isolates identified from dogs is a critical step in 59 antimicrobial stewardship and in the containment of AMR within the One Health framework. 60 The objectives of this study were to: 1) calculate the proportion of antimicrobial susceptible E. 61 coli isolates identified in canine specimens submitted to the Indiana Animal Disease Diagnostic 62 63 Laboratory (ADDL) from January 1, 2010, through December 1, 2019; 2) identify temporal trends in susceptibility among these isolates to individual antimicrobials tested; and 3) to identify 64

the temporal patterns and host risk factors for AMR and multidrug resistance (MDR) amongthese isolates.

67

# 68 Materials and Methods

### 69 Source of data and ethical approval

70 The study was exempted from oversight by the Purdue University Institutional Animal Care and Use Committee (IACUC). We used secondary data obtained from the Indiana ADDL 71 72 and informed consent was not required. No field studies or experiments were conducted in this 73 study, and the study did not directly involve use of animals and posed no risk to clients (animal owners). Data from E. coli isolates phenotypically assessed for AMR from January 1, 2010, 74 through December 31, 2019, were utilized. The variables extracted from the dataset included: the 75 age of the dog, breed, sex, geographic location (localized to zip code) of its home, and host 76 77 source (anatomic location) of isolation of the pathogen.

The antimicrobial susceptibility test (AST) results used in this analysis were obtained 78 79 using a dilution-based method that yielded quantitative data (minimum inhibitory concentration) 80 and the isolates were categorized as susceptible (S), intermediate (I), or resistant (R) based upon Clinical and Laboratory Standards Institute (CLSI) breakpoints. The susceptibility testing was 81 performed for 35 drugs: amikacin, amoxicillin, ampicillin, azithromycin, cefazolin, cefovecin, 82 cefoxitin, cefpodoxime, ceftazidime, ceftiofur, chloramphenicol, chlortetracycline, 83 clarithromycin, clindamycin, danofloxacin, doxycycline, enrofloxacin, erythromycin, florfenicol, 84 85 gentamicin, imipenem, marbofloxacin, neomycin, oxacillin, oxytetracycline, penicillin, rifampin, spectinomycin, sulfadimethoxine, tetracycline, tiamulin, ticarcillin, ticarcillin-clavulanate, 86

tilmicosin, trimethoprim, tulathromycin, and tylosin. Drugs with complete susceptibility data or
with more than 500 isolates tested were considered in these analyses.

89 Overall, 27 antimicrobials from 10 antimicrobial classes were included in the final 90 analyses. The antimicrobial classification conformed with the classification described by Riviere and Papich [6] and the 10 classes included aminoglycosides, the penicillins, cephalosporins and 91 92 cephamycins, carbapenems, amphenicols, fluoroquinolones, macrolides, lincosamides, tetracyclines, and antifolate. All 10 classes belonged to either critically important antimicrobial 93 94 classes for human medicine (e.g. aminoglycosides, carbapenems, penicillins) or highly important 95 antimicrobials (e.g. amphenicols, antifolate) as classified by the World Health Organization 96 (WHO) [7]. For AMR and MDR determination, drugs known to exhibit intrinsic resistance phenotypes in Enterobacteriaceae [8] (e.g. penicillin, oxacillin, clindamycin, and erythromycin) 97 were excluded. 98

99 Data and statistical analysis

Data cleaning and preparation was performed in Microsoft Excel. The data were assessed 100 for completeness, duplicates were removed, and only complete records were included in the 101 102 analyses. Geographic origins of the samples located to zip code were categorized at the county and state spatial scales. The state spatial scale categories were further grouped into within 103 Indiana, out-of-state, and unknown (for those where no geographic origin was reported). The sex 104 105 of the dog was categorized as male, female, or intersex regardless of neuter status. Age was categorized into seven age groups: less than 1 year, 1 to 3 years, over 3 to 6 years, over 6 to 8 106 107 years, over 8 to 10 years, over 10 to 12 years, and greater than 12 years of age as described 108 previously [9]. We removed one case from the age category due to an implausible age designation of 95 years. 109

Dog breeds were grouped based on the American Kennel Club (AKC) breed group 110 classification as described by Conner and colleagues [10]. However, three breeds (English 111 shepherd, Jack Russel terrier, and Pitbull) that were not listed on the AKC grouping system were 112 classified based on the United Kennel Club (UKC) grouping [11]. Dogs identified in the dataset 113 as mixed breed were treated as such in the final grouping. Two breeds (goldendoodle and 114 115 cockapoo) that were not yet recognized by any major kennel club were included in the category mixed. If an animal was identified using a non-specific breed name such as poodle, or schnauzer, 116 117 they were categorized as unknown breed. If breed, sex, or age of the dog was not reported and other data was otherwise complete, it was categorized as "unknown" for the specific category. 118 The anatomic location or specimen source was categorized as: abdominal cavity/fluid, ear 119 120 and ocular, feces, respiratory tract, skin, urine and bladder, uterus, vagina and vulva, wounds, and "all others." The "all others" contained specimen sources with very small counts or those 121 with non-specific identities such as fluid, swabs, tissue etc. All AST results reported as "NI" (no 122 interpretation) were excluded from the analysis. A more conservative approach for categorization 123 of all AST data reported as susceptible, intermediate, or resistant was adopted for this study as 124 previously suggested by Sweeney and others [12] and Magiorakos and others [13]. Briefly, the 125 AST data were grouped into two categories "susceptible" and "not susceptible." The "not 126 susceptible" category included the resistant and/or intermediately susceptible isolates. Isolates 127 128 that were not susceptible to at least one antimicrobial drug were considered to be AMR isolates [10] and isolates that were not susceptible to at least one antimicrobial drug in at least three 129 antimicrobial classes were considered to be MDR [12]. The CLSI guidelines were used in the 130 analysis of the AST results [14]. 131

# **132 Descriptive analyses**

133 Statistical analyses were performed in a SAS commercial statistical software.

Frequencies and proportions were used to summarize the data. The Cochran-Armitage trend testwas used to investigate the temporal trends in the data.

136 L

# Univariable and multivariable analysis

Isolates from intersex dogs and from dogs belonging to the foundation stock service 137 breed group were excluded from the univariable and multivariable analyses due to small counts. 138 Univariable binary logistic regression was used to investigate the association between 139 geographic origin of sample and AMR. A further analysis of the associations between host 140 factors (age, sex, and breed of the dog, specimen source/type and AMR/MDR) were conducted 141 only for samples with a known in-state address. Variables with a *p*-value  $\leq 0.15$  in the 142 143 univariable analysis were considered for inclusion in the multivariable model building. A multivariable binary logistic regression model was built to investigate the association between 144 host factors and AMR. The backward elimination procedure was used to build the multivariable 145 model and only statistically significant predictors ( $P \le 0.05$ ) were retained in the final main 146 effects multivariable model. In the final model, two-way interactions between age and breed 147 were assessed based on biological plausibility and standard multiple pairwise comparisons were 148 obtained using the SAS "LSMEANS" statement. The model fit was assessed using The Hosmer 149 and Lemeshow Goodness-of-Fit Test. Cluster analysis to discern the spatial patterns of 150 AMR/MDR was deemed untenable due to small sample sizes in the different counties in Indiana. 151

152 **Results** 

# 153 Sample characteristics

154	A total of 2,738 E. coli isolates were included in the general analysis of	these data. Of

- these, 1,641 (59.9%) were isolated from samples obtained from female dogs, 881 (32.2%) from
- male dogs, three (0.1%) were from intersex dogs, and 190 (7%) samples were from dogs that did
- not have sex identified. Most of the samples (n=2,058; 75.2%) were identified using an in-state
- zip code while 275 (10%) were identified as being from out-of-state samples; 405 (14.8%)
- samples had no geographic origin reported. Out-of-state samples came from 18 states: Illinois
- 160 (n=175), Michigan (n=23), Ohio (n=23), Maryland (n=10), Tennessee (n=9), Missouri (n=5),
- 161 Georgia (n=5), West Virginia (n=5), California (n=4), Kentucky (n=4), Florida (n=3), Texas
- 162 (n=2), Pennsylvania (n=2), Virginia (n=1), Wisconsin (n=1), Nebraska (n=1), Alabama (n=1),
- and Arkansas (n=1) (Table 1).
- 164 **Table 1**: Characteristics of all *Escherichia coli* isolates tested for antimicrobial susceptibility at
- the Indiana Animal Disease Diagnostic Laboratory, from January 2010 to December 2019.

Sample characteristics	Number (%) of isolates
Geographic origin of sample	N=2,738
Indiana	2,058 (75.2)
Out-of-state	275 (10)
Location not recorded	405 (14.8)
Sex	N = 2,738
Female	1,641 (59.9)
Male	881 (32.2)
Intersex	3 (0.1)
Unknown	213 (7.8)
Age of dog (years)	N = 2,737
<1year	208 (7.6)
1-3years	265 (9.7)
>3-6years	440 (16.1)
>6-8years	413 (15.1)
>8-10years	496 (18.1)
>10-12years	447 (16.3)
>12years	408 (14.9)
Unknown	60 (2.2)
Breed Group	N = 2,738
Mixed breed	583 (21.3)

Sporting	565 (20.6)
Working	312 (11.4)
Hound	256 (9.4)
Terrier	256 (9.4)
Тоу	252 (9.2)
Herding	222 (8.1)
Non-Sporting	200 (7.3)
Unknown	88 (3.2)
Foundation Stock Service	4 (0.2)
Isolation source	N = 2,738
Abdominal cavity and fluid	77 (2.8)
Ear and Ocular	138 (5)
Feces	170 (6.2)
Respiratory tract	101 (3.7)
Skin	45 (1.6)
Urine and bladder	1676 (61.2)
Uterus, vagina, and vulva	59 (2.2)
Wounds	71 (2.6)
All others	401 (14.7)
Year of sample collection	N = 2,738
2010	206 (7.5)
2011	249 (9.1)
2012	228 (8.3)
2013	232 (8.5)
2014	280 (10.2)
2015	257 (9.4)
2016	310 (11.3)
2017	294 (10.7)
2018	355 (13)
2019	327 (12)

166

# 167 Proportions and trends in susceptibility to different antimicrobials

168 Overall, 553 (20.2%) of the isolates were susceptible to 17 of the 27 antimicrobials

169 examined. E. coli susceptibility to marbofloxacin was 78.6% (2,099/2,670) and ranged from

170 83.3% (170/204) susceptible isolates tested in 2010 to 75.7% (234/309) susceptible isolates

tested in 2019. Overall susceptibility to doxycycline was 74.4% (1,999/2,688) and ranged from

172 77.5% (158/204) susceptible isolates tested in 2010 to 72.5 (227/313) susceptible isolates tested

in 2019 (Table 2). Statistically significant temporal trends were observed among 10 of the 27

- antimicrobials evaluated (Table 2). A significant (P < 0.05) downward (decreasing) trend in
- susceptibility was observed for amoxicillin-clavulanic acid, ampicillin, cefalexin, cefazolin,
- 176 ceftazidime, cephalothin, chloramphenicol, and orbifloxacin (Table 2).

- **Table 2**: Trends in antimicrobial susceptibility of *Escherichia coli* isolated from dog specimens tested at the Indiana Animal Disease
- 178 Diagnostic Laboratory, 2010 2019.

Antimicrobial	Antimicrobial	Percenta	ge (num	ber of spe	ecimens t	ested) of	suscepti	ble isola	tes to an	antimicr	obial	Total	Statisti	P-values
class													c (Z)-	(CAT-T)
													САТ-Т	
		2010	2011	2012	2013	2014	2015	2016	2017	2018	2019			
Aminoglycosides														
	Amikacin	97.6	98.8	95.6	96.1	93.9	98.1	97.1	100	99.2	97.3	97.5	-2.1528	0.0157
		(204)	(248)	(226)	(232)	(277)	(257)	(310)	(289)	(354)	(309)	(2706)		
	Gentamycin	86.4	93.6	84.7	83.2	87.9	90.3	89.4	92.9	84.2	89.3	88.2	-0.3426	0.3660
		(206)	(249)	(228)	(232)	(280)	(257)	(310)	(294)	(355)	(327)	(2738)		
Amphenicols	Chloramphenicol	89.2	91.1	83.2	80.6	86.3	80.2	83.9	82.7	75.5	78.8	82.8	4.8084	<.0001
		(203)	(248)	(226)	(232)	(277)	(257)	(310)	(289)	(351)	(217)	(2610)		
Antifolate	Trimethoprim	82 (206)	86.8	75.4	75.9	76.8	81.3	81.9	83.6	74.7	78.5	79.6	1.2911	0.0983
			(249)	(228)	(232	(280)	(257)	(310)	(293)	(348)	(311)	(2714)		
Carbapenem	Imipenem	99 (204)	100	99.1	99.6	98.9	100	99.7	99.3	99.7	98.7	99.4	0.4271	0.3346
			(248)	(226)	(230)	(275)	(256)	(306)	(283)	(336)	(309)	(2673)		
Cefalosporin/Cefa														
mycin														

	Cefalexin	-	-	-	-	-	-	63.5	78.3	61.5	66	67.9	2.1955	0.0141
								(63)	(281)	(327)	(300)	(971)		
	Cefazolin	74.3	75.8	73	68.5	75.1	73.5	59.1	69	54.6	51.4	66.4	8.1388	<.0001
		(202)	(248)	(226)	(232)	(277)	(257)	(308)	(284)	(339)	(313)	(2686)		
	Cefovecin	75 (204)	77	72.1	69.6	78.2	75.8	72.9	84.4	67.4	68.9	74	1.4236	0.0773
			(248)	(226)	(230)	(275)	(256)	(306)	(282)	(331)	(309)	(2667)		
	Cefoxitin	76.5	79.8	74.3	72.6	80.7	82.8	77	0	0(1)	0	77.84	-0.8763	0.1904
		(204)	(248)	(226)	(230)	(275)	(256)	(243)				(1683)		
	Cefpodoxime	74 (204)	76.2	71.7	71.3	77.8	75.4	71.9	84.1	66.7	67.6	73.5	1.6614	0.0483
			(248)	(226)	(230)	(275)	(256)	(306)	(283)	(336)	(309)	(2673)		
	Ceftazidime	-	-	-	-	-	-	85.7	89.7	82.3	81.3	84.4	2.4729	0.0067
								(63)	(281)	(327)	(300)	(971)		
	Ceftiofur	75.2	74.3	71.5	66.4	75.7	73.5	73.3	72.7	85.7	79	73.1	-0.3796	0.3521
		(206)	(249)	(228)	(232)	(280)	(257)	(247)	(11)	(21)	(19)	(1750)		
	Cephalothin	-	76.5	60.2	51.1	-	-	-	0 (2)	0 (9)	7.7	58.7	6.7500	<.0001
			(115)	(226)	(141)						(13)	(506)		
Penicillins														
	Amoxiclav	72.6	67.2	100 (2)	71.4	69.5	76.2	65.6	48.1	46.4	44.4	60.3	9.3130	<.0001
		(204)	(137)		(91)	(275)	(256)	(299)	(283)	(336)	(288)	(2171)		

	Ampicillin	59.2	55.4	50 (2)	55.3	53.6	57.8	50.7	37.2	37.1	38.2	47.7	7.1012	<.0001
		(206)	(139)		(94)	(278)	(256)	(306)	(288)	(337)	(275)	(2183)		
	Penicillin	0 (206)	0	0 (228)	0	0	0	0	0 (7)	0 (12)	0	0	-	-
			(247)		(229)	(276)	(256)	(243)			913)	(1717)		
	Oxacillin	0.5	0.8	2.2	1.3	1.5	0	1.7	0 (2)	0 (10)	7.7	1.2	-0.6857	0.2465
		(204)	(248)	(226)	(230)	(275)	(256)	(243)			(13)	(1707)		
	Piperacillin	-	-	-	-	-	-	100	96.4	97	97.3	97.1	0.2269	0.4103
	tazobactam							(63)	(281)	(326)	(300)	(970)		
	Ticarcillin	60.8	58.1	54.4	52.2	54.9	58.4	63.2	83.3	52.6	72.2	57.6	-0.9315	0.1758
		(204)	(248)	(226)	(232)	(277)	(257)	(247)	(6)	(19)	(18)	(1734)		
	Ticarcillin Clav	72.6	70.2	70.8	64.4	65.5	70.3	67.9	0	0(1)	0	68.6	1.2077	0.1136
		(204)	(248)	(226)	(230)	(275)	(256)	(243)				(1683)		
Fluoroquinolones														
	Enrofloxacin	83 (206)	80.3	74.1	73	79.5	78.9	76.8	91.7	73.3	73.1	78.2	1.0780	0.1405
			(249)	(228)	(230)	(278)	(256)	(306)	(266)	(326)	(309)	(2654)		
	Marbofloxacin	83.3	81.9	74.3	74.4	80.4	78.9	77.5	88.3	73.1	75.7	78.6	1.2731	0.1015
		(204)	(248)	(226)	(230)	(275)	(256)	(306)	(282)	(334)	(309)	(2670)		
	Orbifloxacin	-	-	-	-	-	-	71.4	85.4	72.3	73	76.2	2.3941	0.0083
								(63)	(280)	(325)	(300)	(968)		
	1													

Lincosamide	Clindamycin	0 (206)	0	0 (228)	0	0	0	0	0 (7)	0 (12)	0 (14)	0.06	-2.7964	0.0026
			(249)		(230)	(278)	(256)	(243)				(1723)		
Macrolide	Erythromycin	0 (204)	0	0 (226)	0	0	0	0	-	-	-	0	-	-
			(248)		(232)	(277)	(257)	(202)				(1646)		
Tetracyclines														
	Doxycycline	77.5	76.6	72.1	68.4	75.8	73.4	79.2	75.9	72.1	72.5	74.4	0.5936	0.2764
		(204)	(248)	(226)	(231)	(277)	(256)	(307)	(286)	(340)	(313)	(2688)		
	Tetracycline	-	-	-	-	-	-	81	74.4	70	72.1	72.6	1.3344	0.0910
								(63)	(285)	(327)	(301)	(976)		

# 185 Antimicrobial resistance (AMR) and multi-drug resistance (MDR)

186	The overall percentage of AMR (isolates not susceptible to at least one antimicrobial) in
187	isolates was 61.7% (n=1,690) and 29.3 % (801) of isolates were MDR. Of the 1,690 AMR
188	isolates, 47.4% (801/1,690) were MDR (Table 3). A significant (P=<0.0001) upward trend in
189	AMR was observed while MDR significantly (P=0.0083) decreased (Fig.1). Geographic region
190	of sample origin (e.g., out-of-state versus in-state) was significantly associated with AMR (P
191	<.0001). The odds of an isolate being shown to have resistance to at least one antimicrobial were
192	two times higher in all (combined) out-of-state samples when compared to samples from Indiana
193	(OR: 2.04, 95% CI: 1.54 - 2.7) and the odds of an isolate being shown to have resistance to at
194	least one antimicrobial were 1.89 times higher among samples of unreported (unknown) origin
195	when compared to known Indiana samples (OR: 1.89, 95% CI:1.5 - 2.39).
196	
197	
198	
199	

**Table 3**: Trends in antimicrobial resistance and multidrug resistance among *Escherichia coli* isolated from dog specimens at the

202 Indiana Animal Disease Diagnostic Laboratory, 2010 – 2019.

											Total	Statistic	<i>P</i> -values
		Percer	ntage (nı	umber of		(Z)-	(CAT-T)						
							CAT-T						
	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019			
AMR	49	50.2	59.2	63.8	57.1	54.5	60	72.1	70.7	71	61.7	-7.4123	<.0001
	(206)	(249)	(228)	(232)	(280)	(257)	(310)	(294)	(355)	(327)	(2738)		
MDR	48.5	52.8	56.3	53.4	43.8	49.3	45.2	39.2	48.6	44.4	47.4	2.3959	0.0083
	(101)	(125)	(135)	(148)	(160)	(140)	(186)	(212)	(251)	(232)	(1690)		

- Figure 1: A graphical representation of the temporal trends in antimicrobial resistance and multidrug resistance among *Escherichia*
- *coli* isolated from dog specimens at the Indiana Animal Disease Diagnostic Laboratory, 2010 2019.

# 208 Host factors associated with AMR/MDR in Indiana

- For all samples from known Indiana addresses, 1,191/2,050 (58.1%) were resistant to at
- least one antimicrobial and 859/2,050 (41.9%) were not resistant to any antimicrobials. Of the
- 211 1,191 AMR isolates, 532 (44.7%) were MDR (Table 4).
- **Table 4:** The distribution of isolates from Indiana based on host factors and AMR status.

Host factors	Total number (%) of isolates assessed for AMR	Number AMR iso	· /	Total number (%) of isolates assessed for MDR		Number (%) of MDR isolates		
		No	Yes		No	Yes		
Sex	N = 2050			N=1191				
Female	1239 (60.4)	509	730	730	394	336		
		(24.8)	(35.6)	(61.3)	(33.1)	(28.2)		
Male	617 (30.1)	265	352	352	200	152		
		(12.9)	(17.2)	(29.6)	(16.8)	(12.8)		
Unknown	194 (9.5)	85 (4.2)	109	109	65 (5.5)	44 (3.7)		
			(5.3)	(9.2)				
Age (years)	N = 2050			N=1191				
<1year	177 (8.6)	78 (3.8)	99 (4.8)	99 (8.3)	50 (4.2)	49 (4.1)		
1-3years	209 (10.2)	71 (3.5)	138	138	71 (6)	67 (5.6)		
			(6.7)	(11.6)				
>3-6years	319 (15.6)	137	182	182	105	77 (6.5)		
		(6.7)	(8.9)	(15.3)	(8.8)			
>6-8years	330 (16.1)	161	169	169	95 (8)	74 (6.2)		
		(7.9)	(8.2)	(14.2)				
>8-10years	376 (18.3)	166	210	210	132	78 (6.6)		
		(8.1)	(10.2)	(17.6)	(11)			
>10-12years	310 (15.1)	112	198	198	108 (9)	90 (7.6)		
		(5.5)	(9.7)	(16.6)				
>12years	279 (13.6)	114	165 (8)	165 (14)	82 (7)	83 (7)		
-		(5.6)						
Unknown	50 (2.4)	20 (0.9)	30 (1.5)	30 (2.5)	16 (1.3)	14 (1.2)		
Breed Group	N = 2050			N=1191				
Sporting	457 (22.3)	206	251	251	145	106		
-		(10.1)	(12.2)	(21.1)	(12.2)	(8.9)		

Mixed breed	411 (20.1)	178	233	233	128	105
		(8.7)	(11.4)	(19.6)	(10.8)	(8.8)
Working	225 (11)	100	125	125	68 (5.7)	57 (4.8)
		(4.9)	(6.1)	(10.5)		
Тоу	195 (9.5)	88 (4.3)	107	107 (9)	67 (5.6)	40 (3.4)
-			(5.2)			
Hound	184 (9)	85 (4.2)	99 (4.8)	99 (8.3)	58 (4.9)	41 (3.4)
Terrier	182 (8.9)	53 (2.6)	129	129	69 (5.8)	60 (5)
			(6.3)	(10.8)		
Herding	170 (8.3)	56 (2.7)	114	114	50 (4.2)	64 (5.4)
			(5.6)	(9.6)		
Non-Sporting	147 (7.2)	53 (2.6)	94 (4.6)	94 (7.9)	52 (4.4)	42 (3.5)
Unknown	79 (3.9)	40 (2)	39 (1.9)	39 (3.3)	22 (1.9)	17 (1.4)
<b>Isolation source</b>	N = 2050			N=1191		
Abdominal cavity and	65 (3.2)	26 (1.3)	39 (1.9)	39 (3.3)	26 (2.2)	13 (1.1)
fluid						
Ear and Ocular	112 (5.5)	42 (2.1)	70 (3.4)	70 (5.9)	43 (3.6)	27 (2.3)
Feces	96 (4.7)	32 (1.6)	64 (3.1)	64 (5.4)	36 (3)	28 (2.4)
Respiratory tract	80 (3.9)	17 (0.8)	63 (3.1)	63 (5.3)	27 (2.3)	36 (3)
Skin	30 (1.4)	9 (0.4)	21 (1)	21 (1.8)	13 (1.1)	8 (0.7)
Urine and bladder	1257 (61.3)	584	673	673	374	299
		(28.5)	(32.8)	(56.5)	(31.4)	(25.1)
Uterus, vagina, and	43 (2.1)	23 (1.1)	20 (1)	20 (1.7)	14 (1.2)	6 (0.5)
vulva						
Wounds	52 (2.5)	13 (0.6)	39 (1.9)	39 (3.3)	17 (1.4)	22 (1.9)
All others	315 (15.4)	113	202	202 (17)	109	93 (7.8)
		(5.5)	(9.9)		(9.2)	

213

# 214 Univariable logistic regression

There was no significant unadjusted association between sex and the outcome of AMR,

216 however breed, age, and isolation source had significant associations with AMR (Table 5). There

217 were no significant unadjusted associations between the four host factors and MDR (Table 6).

- **Table 5:** Results of univariable logistic regression models assessing the association of host
- 219 factors with antimicrobial resistance among *Escherichia coli* isolated from dog specimens
- 220 originating from Indiana.

Host factors	Category	OR (95%CI)	<i>P</i> Value
Sex	†Overall	_	0.6338
~ ~ ***	Male vs Female	0.93 (0.76 - 1.13)	0.442
	Male vs Unknown	$\frac{0.05(0.76 - 1.13)}{1.04(0.75 - 1.43)}$	0.832
	Female vs Unknown	$\frac{1.01(0.75 - 1.15)}{1.12(0.82 - 1.52)}$	0.473
Age	<sup>†</sup> Overall		0.0149
1.20	1-3years vs >3-6years	1.46 (1.02 – 2.1)	0.039
	1-3years vs >6-8years	1.85 (1.29 – 2.65)	0.0008
	1-3 years vs >8-10 years	1.54 (1.08 – 2.18)	0.017
	1-3years vs >10-12years	1.1 (0.76 – 1.59)	0.614
	1-3years vs >12years	1.34 (0.93 – 1.95)	0.121
	1-3years vs Unknown	1.3 (0.69 – 2.44)	0.423
	1-3years vs <1year	1.53 (1.01 – 2.31)	0.043
	>3-6years vs >6-8years	1.27 (0.93 – 1.73)	0.136
	>3-6years vs >8-10years	1.05 (0.78 – 1.42)	0.750
	>3-6years vs>10-12years	0.75 (0.55 – 1.04)	0.081
	>3-6years vs >12years	0.92 (0.66 – 1.27)	0.606
	>3-6years vs Unknown	0.89 (0.48 - 1.63)	0.695
	>3-6years vs <1year	1.05(0.72 - 1.52)	0.809
	>6-8years vs >8-10years	0.83 (0.62 – 1.12)	0.218
	>6-8years vs >10-12years	0.59 (0.43 - 0.82)	0.001
	>6-8years vs >12years	0.73(0.53-1)	0.05
	>6-8years vs Unknown	0.7 (0.38 - 1.28)	0.248
	>6-8years vs <1year	0.83 (0.57 – 1.19)	0.310
	>8-10years vs >10-12years	0.72 (0.53 – 0.94)	0.034
	>8-10years vs >12years	0.87(0.64 - 1.2)	0.4
	>8-10years vs Unknown	0.84 (0.46 - 1.54)	0.579
	>8-10years vs <1year	1 (0.7 – 1.43)	0.986
	>10-12years vs >12years	1.22 (0.88 – 1.7)	0.239
	>10-12years vs Unknown	1.18 (0.64 - 2.17)	0.598
	>10-12years vs <1year	1.39 (0.96 - 2.03)	0.085
	>12years vs Unknown	0.97 (0.52 - 1.78)	0.909
	>12years vs <1year	1.14 (0.78 - 1.67)	0.499
	Unknown vs <1 year	1.18 (0.62 - 2.24)	0.608
Breed group	†Overall	-	0.0007
• •	Hound vs Mixed	0.89 (0.63 - 1.26)	0.512
	Hound vs non-Sporting	0.66 (0.42 - 1.02)	0.064
	Hound vs Sporting	0.96 (0.68 – 1.35)	0.797
	Hound vs Terrier	0.48 (0.31 – 0.74)	0.0008
	Hound vs Toy	0.96 (0.64 - 1.44)	0.835
	Hound vs Unknown	1.2 (0.71 – 2.03)	0.509
	Hound vs Working	0.93 (0.63 - 1.38)	0.723
	Hound vs Herding	0.57 (0.37 – 0.88)	0.011
	Mixed vs non-Sporting	0.74 (0.5 – 1.09)	0.126

		1.07 (0.02 1.41)	0.001
	Mixed vs Sporting	1.07 (0.82 - 1.41)	0.601
	Mixed vs Terrier	0.54(0.37 - 0.78)	0.001
	Mixed vs Toy	1.08 (0.76 – 1.52)	0.673
	Mixed vs Unknown	1.34 (0.83 – 2.18)	0.231
	Mixed vs Working	1.05 (0.76 - 1.45)	0.783
	Mixed vs Herding	0.64 (0.44 – 0.94)	0.021
	Non-Sporting vs Sporting	1.46 (0.99 – 2.14)	0.055
	Non-Sporting vs Terrier	0.73 (0.46 – 1.16)	0.182
	Non-Sporting vs Toy	1.46 (0.94 – 2.26)	0.092
	Non-Sporting vs Unknown	1.82 (1.04 – 3.17)	0.035
	Non-Sporting vs Working	1.42 (0.93 - 2.18)	0.109
	Non-Sporting vs Herding	0.87 (0.55 – 1.39)	0.561
	Sporting vs Terrier	0.5(0.35 - 0.72)	0.0002
	Sporting vs Toy	1 (0.72 – 1.4)	0.99
	Sporting vs Unknown	1.25 (0.78 - 2.02)	0.361
	Sporting vs Working	0.98 (0.71 - 1.34)	0.876
	Sporting vs Herding	0.6(0.41 - 0.87)	0.006
	Terrier vs Toy	2 (1.31 – 3.07)	0.001
	Terrier vs Unknown	2.5 (1.45 – 4.3)	0.001
	Terrier vs Working	1.95 (1.29 – 2.95)	0.002
	Terrier vs Herding	1.2 (0.76 – 1.88)	0.439
	Toy vs Unknown	1.25(0.74-2.11)	0.408
	Toy vs Working	0.97 (0.66 - 1.43)	0.888
	Toy vs Herding	0.6(0.39 - 0.92)	0.018
	Unknown vs Working	0.78(0.47 - 1.3)	0.343
	Unknown vs Herding	0.48(0.28-0.83)	0.008
	Working vs Herding	0.61 (0.41 - 0.93)	0.02
	<sup>†</sup> Overall	<u> </u>	<.0001
Sample	Ear & ocular vs Feces	0.83 (0.47 - 1.48)	0.532
source/sample type	Ear & ocular vs Respiratory tract	0.45 (0.23 - 0.87)	0.017
source, sumpre type	Ear & ocular vs Skin	0.71(0.3-1.7)	0.448
	Ear & ocular vs Urine & bladder	1.45 (0.97 - 2.15)	0.069
	Ear & ocular vs Uterus, vagina,	1.43(0.97 - 2.13) 1.92(0.94 - 3.9)	0.073
	vulva	1.92 (0.94 5.9)	0.075
	Ear & ocular vs Wounds	0.56 (0.27 – 1.16)	0.117
	Ear & ocular vs All others	0.93(0.6 - 1.46)	0.758
	Ear & ocular vs Abdominal	1.1(0.59 - 2.08)	0.738
	cavity/fluid	1.1(0.5) - 2.00)	0.742
	Feces vs Respiratory tract	0.54 (0.27 – 1.07)	0.077
	Feces vs Skin	0.86(0.35 - 2.09)	0.734
	Feces vs Urine & bladder	1.74(1.12-2.69)	0.014
	Feces vs Uterus, vagina, vulva	2.3(1.1-4.79)	0.026
	Feces vs Wounds	0.67 (0.31 - 1.42)	0.294
	Feces vs All others	1.12(0.69 - 1.81)	0.649
	Feces vs Abdominal cavity/fluid	1.3(0.69 - 2.56)	0.389
	Trees vs Audominiai Cavity/IIdid	1.3(0.09 - 2.30)	0.307

Respiratory tract vs Skin	1.59 (0.62 - 4.09)	0.338
Respiratory tract vs Urine & bladder	3.2 (1.86 - 5.56)	<.0001
Respiratory tract vs Uterus, vagina, vulva	4.26 (1.91 – 9.52)	0.0004
Respiratory tract vs wounds	1.24 (0.54 - 2.82)	0.616
Respiratory tract vs all others	2.07 (1.16 – 3.71)	0.014
Respiratory tract vs Abdominal cavity/fluid	2.47 (1.19 – 5.13)	0.015
Skin vs Urine & bladder	2.03 (0.92 - 4.46)	0.08
Skin vs Uterus, vagina, vulva	2.68 (1 - 7.18)	0.049
Skin vs Wounds	0.78 (0.29 - 2.12)	0.623
Skin vs All others	1.31 (0.58 - 2.95)	0.521
Skin vs Abdominal cavity/fluid	1.56 (0.62 - 3.92)	0.349
Urine & bladder vs Uterus, vagina, vulva	1.33 (0.72 – 2.44)	0.365
Urine & bladder vs Wounds	0.38(0.2-0.73)	0.003
Urine & bladder vs All others	0.65(0.5-0.83)	0.0008
Urine & bladder vs Abdominal cavity/fluid	0.77 (0.46 - 1.28)	0.31
Uterus, vagina, vulva vs Wounds	0.29 (0.12 - 0.69)	0.005
Uterus, vagina, vulva vs All others	0.49 (0.26 - 0.92)	0.028
Uterus, vagina, vulva vs Abdominal cavity/fluid	0.58 (0.27 – 1.26)	0.17
Wounds vs All others	1.68 (0.86 - 3.28)	0.129
Wounds vs Abdominal cavity/fluid	2 (0.9 - 4.45)	0.09
All others vs Abdominal cavity/fluid	1.19 (0.69 – 2.06)	0.53
Overall = overall effect of host factor on AMR		

- **Table 6:** Results of univariable logistic regression models assessing the association of host
- factors with multi-drug resistance among *Escherichia coli* isolated from dog specimens
- 224 originating from Indiana.

Host factors	Category	OR (95%CI)	P Value
Sex	<sup>†</sup> Overall	—	0.4330
	Male vs Female	0.89 (0.69 – 1.15)	0.378
	Male vs Unknown	1.12 (0.73 – 1.74)	0.604

	Female vs Unknown	1.26 (0.84 – 1.9)	0.269
Age	<sup>†</sup> Overall		0.2377
	1-3years vs >3-6years	1.29 (0.83 – 2.01)	0.267
	1-3years vs >6-8years	1.21 (0.77 – 1.9)	0.405
	1-3years vs >8-10years	1.6 (1.03 – 2.47)	0.035
	1-3years vs >10-12years	1.13 (0.73 – 1.75)	0.576
	1-3years vs >12years	0.93 (0.59 - 1.47)	0.761
	1-3years vs Unknown	1.08 (0.49 - 2.38)	0.852
	1-3years vs <1year	0.96 (0.58 - 1.6)	0.886
	>3-6years vs >6-8years	0.94 (0.62 - 1.44)	0.78
	>3-6years vs >8-10years	1.24 (0.83 - 1.86)	0.297
	>3-6years vs >10-12years	0.88 (0.59 - 1.32)	0.537
	>3-6years vs >12years	0.72 (0.47 - 1.11)	0.136
	>3-6years vs Unknown	0.84 (0.39 - 1.82)	0.655
	>3-6years vs <1year	0.75 (0.46 - 1.22)	0.248
	>6-8years vs >8-10years	1.32 (0.87 – 1.99)	0.19
	>6-8years vs >10-12years	0.94 (0.62 - 1.41)	0.749
	>6-8years vs >12years	0.77 (0.5 – 1.18)	0.233
	>6-8years vs Unknown	0.89 (0.41 – 1.94)	0.77
	>6-8years vs <1year	0.8 (0.48 - 1.31)	0.366
	>8-10years vs >10-12years	0.71 (0.48 - 1.05)	0.089
	>8-10years vs >12years	0.58 (0.39 - 0.88)	0.011
	>8-10years vs Unknown	0.68 (0.31 – 1.46)	0.318
	>8-10years vs <1year	0.6 (0.37 – 0.98)	0.04
	>10-12years vs >12years	0.82 (0.54 – 1.25)	0.357
	>10-12years vs Unknown	0.95 (0.44 - 2.06)	0.901
	>10-12years vs <1year	0.85 (0.52 – 1.38)	0.511
	>12years vs Unknown	1.16 (0.53 – 2.52)	0.714
	>12years vs <1year	1.03 (0.63 - 1.7)	0.899
	Unknown vs <1year	0.89(0.39 - 2.02)	0.786
Breed group	†Overall		0.3
BF	Hound vs Mixed	0.86 (0.54 - 1.39)	0.54
	Hound vs non-Sporting	0.88 (0.5 – 1.55)	0.647
	Hound vs Sporting	0.97 (0.6 – 1.55)	0.889
	Hound vs Terrier	0.81 (0.48 - 1.38)	0.443
	Hound vs Toy	1.18 (0.68 – 2.07)	0.554
	Hound vs Unknown	0.92 (0.43 – 1.93)	0.816
	Hound vs Working	0.84 (0.5 - 1.44)	0.531
	Hound vs Herding	0.55 (0.32 - 0.95)	0.033
	Mixed vs non-Sporting	1.02 (0.63 - 1.64)	0.95
	Mixed vs hon Sporting	1.12 (0.78 – 1.61)	0.53
	Mixed vs Sporting	0.94 (0.61 – 1.45)	0.791
	Mixed vs Toy	1.37 (0.86 - 2.2)	0.184
	Mixed vs Toy Mixed vs Unknown	1.06(0.54-2.1)	0.864
	Mixed vs Unknown Mixed vs Working	0.98 (0.63 - 1.51)	0.804

	Mixed va Herdine	0.64(0.41 - 1.01)	0.052
	Mixed vs Herding	0.64 (0.41 - 1.01)	0.053
	Non-Sporting vs Sporting	1.11(0.69 - 1.78)	0.682
	Non-Sporting vs Terrier	0.93 (0.55 - 1.58)	0.786
	Non-Sporting vs Toy	1.35 (0.77 – 2.38)	0.294
	Non-Sporting vs Unknown	1.05 (0.49 – 2.22)	0.908
	Non-Sporting vs Working	0.96 (0.56 – 1.65)	0.892
	Non-Sporting vs Herding	0.63 (0.36 - 1.09)	0.101
	Sporting vs Terrier	0.84 (0.55 – 1.29)	0.426
	Sporting vs Toy	1.22 (0.77 – 1.95)	0.393
	Sporting vs Unknown	0.95 (0.48 - 1.87)	0.873
	Sporting vs Working	0.87 (0.57 – 1.34)	0.535
	Sporting vs Herding	0.57 (0.37 – 0.89)	0.014
	Terrier vs Toy	1.46 (0.86 - 2.46)	0.158
	Terrier vs Unknown	1.13(0.55 - 2.32)	0.748
	Terrier vs Working	1.04 (0.63 – 1.7)	0.884
	Terrier vs Herding	0.68 (0.41 – 1.13)	0.135
	Toy vs Unknown	0.77(0.37 - 1.63)	0.497
	Toy vs Working	0.71 (0.42 – 1.21)	0.207
	Toy vs Herding	0.47 (0.27 – 0.8)	0.006
	Unknown vs Working	0.92(0.45 - 1.9)	0.826
	Unknown vs Herding	0.6 (0.29 – 1.26)	0.177
	Working vs Herding	0.66 (0.39 - 1.09)	0.104
	<sup>†</sup> Overall	-	0.1856
Sample	Ear & ocular vs Feces	0.81 (0.41 - 1.61)	0.543
source/sample type	Ear & ocular vs Respiratory tract	0.47 (0.24 - 0.94)	0.033
	Ear & ocular vs Skin	1.02(0.37 - 2.78)	0.969
	Ear & ocular vs Urine & bladder	0.79(0.47 - 1.3)	0.348
	Ear & ocular vs Uterus, vagina,	1.47 (0.5 - 4.27)	0.485
	vulva		0.405
	Ear & ocular vs Wounds	0.49 (0.22 - 1.08)	0.075
	Ear & ocular vs All others	0.74 (0.42 - 1.28)	0.073
	Ear & ocular vs Abdominal	1.26 (0.55 - 2.86)	0.279
	cavity/fluid	1.20(0.55 - 2.00)	0.307
	<b>V</b>	0.58 (0.29 - 1.18)	0.132
	Feces vs Respiratory tract Feces vs Skin	1.26 (0.46 - 3.47)	0.132
	Feces vs Urine & bladder	0.97 (0.58 - 1.63)	0.917
	Feces vs Uterus, vagina, vulva	1.81 (0.62 - 5.32)	0.278
	Feces vs Wounds	0.6(0.27 - 1.34)	0.214
	Feces vs All others	0.91 (0.52 - 1.61)	0.749
	Feces vs Abdominal cavity/fluid	1.56 (0.68 - 3.56)	0.296
	Respiratory tract vs Skin	2.18(0.79-5.96)	0.134
	Respiratory tract vs Urine & bladder	1.67 (0.99 – 2.81)	0.055
	Respiratory tract vs Uterus, vagina, vulva	3.1 (1.06 – 9.15)	0.039

	Respiratory tract vs wounds	1.03 (0.46 – 2.31)	0.942
	Respiratory tract vs all others	1.56 (0.88 – 2.77)	0.125
	Respiratory tract vs Abdominal	2.67 (1.16 – 6.13)	0.021
	cavity/fluid		
	Skin vs Urine & bladder	0.77 (0.32 – 1.88)	0.566
	Skin vs Uterus, vagina, vulva	1.44 (0.39 – 5.27)	0.586
	Skin vs Wounds	0.48 (0.16 - 1.42)	0.179
	Skin vs All others	0.72 (0.29 - 1.82)	0.488
	Skin vs Abdominal cavity/fluid	1.23 (0.41 – 3.71)	0.713
	Urine & bladder vs Uterus,	1.87 (0.71 – 4.91)	0.207
	vagina, vulva		
	Urine & bladder vs Wounds	0.62 (0.32 - 1.18)	0.147
	Urine & bladder vs All others	0.94 (0.68 - 1.29)	0.686
	Urine& bladder vs Abdominal	1.6 (0.81 – 3.17)	0.178
	cavity/fluid		
	Uterus, vagina, vulva vs Wounds	0.33 (0.11 – 1.04)	0.059
	Uterus, vagina, vulva vs All	0.5 (0.19 – 1.36)	0.175
	others		
	Uterus, vagina, vulva vs	0.86(0.27 - 2.75)	0.796
	Abdominal cavity/fluid		
	Wounds vs All others	1.52 (0.76 - 3.01)	0.237
	Wounds vs Abdominal	2.59 (1.03 - 6.49)	0.043
	cavity/fluid		
	All others vs Abdominal	1.71 (0.83 – 3.51)	0.146
1			

225

# 226 Adjusted associations

All host factors found to be widely significantly associated ( $P \le 0.15$ ) with AMR in the univariable logistic regression models were included in the multivariable logistic regression analyses. Thus, for AMR, age (P=0.0149), breed (P=0.0007) and sample source/sample type (P<.0001) were included in the multivariable model. All three host factors were retained in the final multivariable model (Table 7) which showed significant associations between AMR and age (P=0.009), breed (P=0.0007), and sample isolation site/source (P<0.0001). The Hosmer and Lemeshow Goodness-of-Fit Test showed that this model best fit these data ( $\chi^2= 8.05$ , DF=8,

234	P=0.429). The multivariable model showed that controlling for breed and specimen source, the
235	odds of AMR in isolates from dogs aged 1 to 3 years were 1.63 times as high as the AMR odds
236	in isolates from dogs aged between 6 and 8 years and isolates from dogs aged greater than 10
237	years were more likely to be antimicrobial resistant than those isolated from other age groups.
238	Based on the non-significant unadjusted associations (using a liberal $\alpha = 0.15$ ), a multivariable
239	model for the association between the host factors and MDR was not built.

- 240 **Table 7**: Multivariable binary logistic regression model of the associations between host factors

241	and antimicrobial resistance amo	ng Escherichia coli isolated	d from samples from Indiana.
-----	----------------------------------	------------------------------	------------------------------

Host factors	Category	OR (95% CI)	<i>P</i> Value
Age	<sup>†</sup> Overall	—	0.009
	1-3years vs >3-6years	1.31 (0.9 – 1.9)	0.159
	1-3years vs >6-8years	1.63 (1.13 – 2.36)	0.009
	1-3years vs >8-10years	1.35 (0.94 – 1.94)	0.103
	1-3years vs >10-12years	0.89 (0.61 – 1.3)	0.543
	1-3years vs >12years	1.08 (0.73 – 1.59)	0.718
	1-3years vs Unknown	1.14 (0.59 – 2.2)	0.697
	1-3years vs <1year	1.5 (0.98 - 2.29)	0.064
	>3-6years vs >6-8years	1.25 (0.91 – 1.72)	0.167
	>3-6years vs >8-10years	1.04 (0.76 - 1.41)	0.83
	>10-12years vs >3-6years	1.47 (1.06 - 2.05)	0.023
	>3-6years vs >12years	0.82 (0.58 - 1.16)	0.264
	>3-6years vs Unknown	0.87 (0.46 - 1.64)	0.671
	>3-6years vs <1year	1.15 (0.78 - 1.69)	0.493
	>6-8years vs >8-10years	0.83 (0.61 - 1.12)	0.221
	>10-12years vs >6-8years	1.84 (1.33 - 2.55)	0.0003
	>12years vs >6-8years	1.52 (1.09 – 2.12)	0.014
	>6-8years vs Unknown	0.7 (0.37 – 1.31)	0.26
	>6-8years vs <1year	0.92 (0.62 - 1.35)	0.654
	>10-12years vs >8-10years	1.52 (1.11 – 2.1)	0.009
	>8-10years vs >12years	0.8 (0.58 - 1.1)	0.165
	>8-10years vs Unknown	0.84 (0.45 - 1.57)	0.591
	>8-10years vs <1year	1.11 (0.76 – 1.62)	0.598
	>10-12years vs >12years	1.21 (0.86 - 1.7)	0.271
	>10-12years vs Unknown	1.28 (0.68 - 2.42)	0.442
	>10-12years vs <1year	1.69 (1.13 – 2.51)	0.01
	>12years vs Unknown	1.06 (0.56 - 2.01)	0.858

	>12years vs <1year	1.39 (0.93 – 2.09)	0.11
	Unknown vs <1 year	1.31 (0.68 – 2.55)	0.422
Breed group	<sup>†</sup> Overall	—	0.0007
	Hound vs Mixed	0.92 (0.64 - 1.31)	0.632
	Hound vs non-Sporting	0.67 (0.42 - 1.05)	0.081
	Hound vs Sporting	0.94 (0.66 - 1.35)	0.749
	Hound vs Terrier	0.47(0.3-0.73)	0.0008
	Hound vs Toy	0.97 (0.64 – 1.46)	0.865
	Hound vs Unknown	1.3 (0.75 – 2.25)	0.343
	Hound vs Working	0.93(0.62 - 1.41)	0.742
	Herding vs Hound	1.68 (1.08 - 2.63)	0.022
	Mixed vs non-Sporting	0.73 (0.49 - 1.08)	0.114
	Mixed vs Sporting	1.03 (0.78 – 1.36)	0.832
	Terrier vs Mixed	1.95 (1.33 – 2.86)	0.0006
	Mixed vs Toy	1.05 (0.74 – 1.49)	0.772
	Mixed vs Unknown	1.42 (0.87 – 2.34)	0.165
	Mixed vs Working	1.02 (0.73 – 1.43)	0.913
	Mixed vs Herding	0.65(0.44 - 0.95)	0.027
	Non-Sporting vs Sporting	1.42(0.96-2.1)	0.079
	Non-Sporting vs Terrier	0.71(0.44 - 1.13)	0.15
	Non-Sporting vs Toy	1.45(0.93-2.28)	0.104
	Non-Sporting vs Unknown	1.96(1.11 - 3.47)	0.021
	Non-Sporting vs Working	1.4(0.91-2.17)	0.127
	Non-Sporting vs Herding	0.89(0.56 - 1.43)	0.642
	Terrier vs Sporting	2.01 (1.38 - 2.93)	0.0003
	Sporting vs Toy	1.02(0.72 - 1.44)	0.9
	Sporting vs Unknown	1.38(0.84 - 2.26)	0.2
	Sporting vs Working	0.99(0.71 - 1.38)	0.949
	Sporting vs Herding	0.63 (0.43 - 0.92)	0.016
	Terrier vs Toy	2.06(1.33 - 3.2)	0.010
	Terrier vs Unknown	2.78(1.59 - 4.86)	0.0003
	Terrier vs Working	1.99(1.3 - 3.06)	0.000
	Terrier vs Herding	1.99(1.9-9.00) 1.27(0.8-2.01)	0.317
	Toy vs Unknown	1.27(0.0-2.01) 1.35(0.79-2.32)	0.275
	Toy vs Working	0.97 (0.65 - 1.44)	0.273
	Herding vs Toy	1.62(1.05 - 2.51)	0.072
	Unknown vs Working	0.72 (0.42 - 1.22)	0.03
	Unknown vs Herding	0.72(0.42 - 1.22) 0.46(0.26 - 0.8)	0.22
	Herding vs Working	1.57 (1.03 - 2.4)	0.000
	†Overall	-1.57(1.05-2.4)	<.0001
Sample	Ear & ocular vs Feces	- 0.8 (0.45 - 1.43)	0.446
source/sample type		· · · · · · · · · · · · · · · · · · ·	
source/sample type	Respiratory tract vs Ear & ocular	2.2(1.12 - 4.34)	0.023
	Ear & ocular vs Skin Ear & ocular vs Urine & bladder	$\begin{array}{c} 0.9 \ (0.37 - 2.18) \\ 1.59 \ (1.06 - 2.39) \end{array}$	0.814

Ear & ocular vs Uterus, vagina,	1.91 (0.92 – 3.94)	0.081
vulva		
Ear & ocular vs Wounds	0.64 (0.3 – 1.35)	0.24
Ear & ocular vs All others	0.97 (0.61 – 1.53)	0.889
Ear & ocular vs Abdominal	1.24 (0.66 – 2.35)	0.504
cavity/fluid		
Feces vs Respiratory tract	0.57 (0.28 - 1.15)	0.115
Feces vs Skin	1.13 (0.46 – 2.79)	0.795
Feces vs Urine & bladder	1.99 (1.27 – 3.13)	0.003
Feces vs Uterus, vagina, vulva	2.39 (1.13 – 5.04)	0.022
Feces vs Wounds	0.8 (0.37 – 1.73)	0.573
Feces vs All others	1.22 (0.74 – 1.99)	0.44
Feces vs Abdominal cavity/fluid	1.56 (0.8 - 3.04)	0.191
Respiratory tract vs Skin	1.98 (0.75 - 5.2)	0.166
Respiratory tract vs Urine &	3.5 (1.99 - 6.13)	<.0001
bladder		
Respiratory tract vs Uterus,	4.2 (1.84 - 9.56)	0.0006
vagina, vulva		
Respiratory tract vs wounds	1.41 (0.61 – 3.26)	0.425
Respiratory tract vs all others	2.13 (1.18 – 3.86)	0.013
Respiratory tract vs Abdominal	2.74(1.3-5.77)	0.008
cavity/fluid		
Skin vs Urine & bladder	1.77 (0.79 – 3.94)	0.165
Skin vs Uterus, vagina, vulva	2.12 (0.78 – 5.77)	0.141
Skin vs Wounds	0.71 (0.26 – 1.96)	0.511
Skin vs All others	1.08 (0.47 - 2.46)	0.861
Skin vs Abdominal cavity/fluid	1.38(0.54 - 3.54)	0.499
Urine & bladder vs Uterus,	1.2(0.64 - 2.24)	0.566
vagina, vulva		0.000
Wounds vs Urine & bladder	2.49 (1.3 – 4.74)	0.006
Urine & bladder vs All others	0.61 (0.47 - 0.8)	0.0003
Urine& bladder vs Abdominal	0.78(0.47 - 1.32)	0.356
cavity/fluid	0.70 (0.17 1.52)	0.550
Wounds vs Uterus, vagina, vulva	2.98 (1.24 - 7.2)	0.015
Uterus, vagina, vulva vs All	0.51 (0.26 - 0.98)	0.042
others	0.51 (0.20 0.90)	0.042
Uterus, vagina, vulva vs	0.65 (0.3 – 1.44)	0.29
Abdominal cavity/fluid	0.05 (0.5 1.44)	0.27
Wounds vs All others	1.52 (0.77 – 2.98)	0.23
Wounds vs Ahl outers	1.95(0.87 - 4.37)	0.23
cavity/fluid	1.95(0.07 - 4.57)	0.107
All others vs Abdominal	1.28 (0.74 – 2.24)	0.378
cavity/fluid	1.20(0.74 - 2.24)	0.578

<sup>†</sup>Overall = overall effect of host factor on AMR

# 243 Discussion

In the present study, we found significant trends in susceptibility, total AMR and MDR in 244 245 canine E. coli isolates, and we identified significant associations between AMR and dog age, 246 breed, and the source of the specimens. We found significant declines in the susceptibility to cefalexin, cefazolin, and cephalothin which are 1<sup>st</sup> generation cephalosporins and to cefpodoxime 247 248 and ceftazidime which are 3<sup>rd</sup> generation cephalosporins. Similar to our study, a previous study found high level resistance to commonly used beta lactams (penicillins, cephalosporins) in dogs 249 250 in the United States [15]. Particularly, 39.7% of all the isolates in the present study were not 251 susceptible to amoxicillin-clavulanic acid and 52.3% were not susceptible to ampicillin, and susceptibility to these drugs significantly declined over time. Similar to our findings, a previous 252 253 study by Thungrat and others reported high-level resistance (45%) to amoxicillin-clavulanic acid and 52.7% to ampicillin among E. coli isolated from dogs in the United States [15]. It is 254 important to note that amoxicillin-clavulanic acid is the most commonly prescribed antimicrobial 255 in many veterinary practices [16–18] and ampicillin is also commonly used to treat bacterial 256 infections in dogs [15]. Therefore, the decreasing trend in the proportion of isolates susceptible 257 to antimicrobials in the beta lactam group in this study could be due to selection pressure from 258 antimicrobial use. For the fluoroquinolone drugs, 21.8% of all the isolates tested were not 259 susceptible to enrofloxacin. A previous study conducted in the northeastern US reported that 260 261 nearly 20% of the *E. coli* isolated from dogs during the period 2004 - 2011 were resistant to enrofloxacin [19]. Also, among the fluoroquinolone antimicrobials, the decline in susceptibility 262 to orbifloxacin observed could be associated with selection pressure from antimicrobial use. 263

The level of AMR in *E. coli* is a good indicator of AMR in bacterial pathogens of dogs and other species [20,21] because of its ubiquitous nature and its ability to act as a reservoir of

266	AMR genes that can transferred to other pathogens through horizontal gene transfer [22].
267	Additionally, AMR in E. coli is suggested to be a good sentinel of the effects of selective
268	pressure from AMU [23]. Therefore, the significant increase in AMR E. Coli observed in this
269	study could be an indicator of an increasing AMR trend among other pathogenic bacteria in the
270	dog populations served by this diagnostic laboratory. This suggests for a need for more concerted
271	efforts in controlling AMR in small animal practice through judicious AMU. The decreasing
272	trend observed for MDR could have resulted from the varying susceptibility trends observed for
273	individual antimicrobials where some individual drugs had decreasing susceptibility trends while
274	others had increasing susceptibility. Corner and others attributed similar decreases in MDR in
275	Staphylococcus spp. to variability in individual drug susceptibility [10].
276	The total lack of susceptibility to clindamycin and erythromycin observed is due to
277	intrinsic resistance [8]. Enterobacteriaceae such as E. coli are known to be intrinsically resistant

information is provided here to guide veterinary clinicians who might find it useful whendeciding which antimicrobial to select.

278

to lincosamides and macrolides such as clindamycin and erythromycin respectively. This

We found high susceptibility of the isolates to amikacin (97.6% susceptibility in 2010 281 and 97.3% in 2019) and observed a significant increase in susceptibility to this drug. Similar to 282 our findings, a previous study that investigated the antimicrobial susceptibility patterns of E. coli 283 in dogs and cats in the United States found only 0.7% of 2,390 canine E. coli isolates were 284 resistant to amikacin [15]. Another study in Canada found 93.8% of 3,364 canine E. coli isolates 285 were susceptible to Amikacin [17]. The high susceptibility and increasing trend in susceptibility 286 287 to amikacin observed in the present study could be indicative of limited use of this antimicrobial in small animal practice in Indiana. The limited use of this drug could be associated with 288

concerns about aminoglycoside toxicity. Similar to the results in amikacin, we found a near 289 perfect susceptibility to imipenem suggesting that imipenem is rarely used in the treatment of 290 bacterial diseases of dogs in Indiana. Imipenem belongs to the carbapenem antimicrobial class 291 and is used in the treatment of multidrug resistant Enterobacteriaceae e.g. E. coli [24]. Perhaps 292 this finding could reflect adherence by small animal clinicians to the guidelines for carbapenem 293 294 use provided by the International Society for Companion Animal Infectious Diseases (ISCAID). The ISCAID recommends that carbapenems should be used only if the pathogen is proven to be 295 resistant to all other reasonable antimicrobial options and susceptibility to the carbapenem 296 297 chosen is documented [24].

In the present study, 61% of the E. coli isolates were found in specimens submitted from 298 the urinary tract. This finding is similar to the findings in previous studies in the U.S. where most 299 of the *E. coli* were isolated from the urinary tract [15,19]. This suggests that urinary tract 300 infections could have been the major reason for canine sample submission to this laboratory. 301 302 However, 3.7% of the *E. coli* isolates were from the respiratory tract and these respiratory tract isolates were more likely to be antimicrobial resistant than those isolated from the urogenital 303 tract (urine, bladder, uterus, vagina, and vulva), and the abdominal cavity. This is in contrast to a 304 305 previous study in the north eastern United States which reported that multidrug resistance was more likely among urinary E. coli than in E. coli isolated from other canine body sites [19]. E 306 307 .coli is known to be involved in respiratory tract infections in dogs and has been isolated from respiratory tract samples [25,26]. Possibly, the higher AMR observed in the respiratory tract 308 isolates in our study could be due to selection pressure resulting from AMU targeting respiratory 309 tract infections in these dogs. There is a need for an in-depth study of AMR among E. coli 310 causing respiratory disease. 311

In the present study, we found that E. coli isolated from dogs older than 10 years were 312 more likely to be resistant to antimicrobials when compared to E. coli isolated from younger 313 dogs after controlling for breed and specimen source. This finding could be due to selection 314 pressure from prior/routine antimicrobial use in dogs in this category since dogs older than 10 315 years are more likely to have been treated with antimicrobials multiple times when compared to 316 317 younger dogs. Previous studies found prior use of antimicrobials was a risk factor for AMR in dogs [27,28] and AMR E. coli was common among vet-visiting dogs [29]. Specifically, prior 318 exposure to some antimicrobials such as fluoroquinolones may select for antimicrobial resistant 319 320 E. coli in dogs that could persist long after antimicrobial therapy [30,31]. Recurrent E. coli infections are possible because *E. coli* possess multiple adaptations for survival and persistence 321 in the host [32]. Dogs older than 10 years are generally considered geriatric and are likely to 322 323 have weakened immune systems due to old age, and as a result, could be susceptible to frequent infections necessitating antimicrobial use. Also, selection pressure from prior AMU could be the 324 325 reason why isolates from dogs aged 1 to 3 years were 1.63 times more likely to be antimicrobial resistant when compared to those from dogs between 6 and 8 years of age. From a public health 326 standpoint, the role of dogs aged older than 10 years and those aged 1 to 3 years in the 327 328 dissemination of AMR E. coli needs to be further investigated. The implications are that humans in close contact with dogs in these age groups would be at a higher risk of exposure to AMR E. 329 330 *coli*. Veterinarians should be made aware of the potential role of dogs aged older than 10 years 331 and those aged 1 to 3 years in the spread of AMR E. coli. Generally, owners of older dogs need to be aware of the AMR E. coli risk in older dogs and should be encouraged to observe infection 332 333 prevention measures such as hand washing with soap and clean water after handling their 334 animals.

335	The association between AMR and breed reported in this study is surprising. We found
336	that terriers and herding dogs were more likely to harbor AMR E. coli when compared to other
337	breed categories. This is an interesting finding that needs to be further investigated as no
338	previous study has elucidated this.

One limitation of this study was the lack of data related the clinical history of the dogs from which samples were collected. This prevented us from discerning the severity of the disease the dog presented with. Further, the lack of specific information regarding prior antimicrobial use in the dogs included in the study limits the inferences that can be made regarding AMU and its relationship with subsequent development of AMR.

### 344 Conclusions

Our findings suggest that AMR in *E. coli* in dogs could be increasing in the state of Indiana. Dogs aged more than 10 years and those aged 1 to 3 years could play a role in the spread of AMR. *E. coli* in dogs in Indiana are likely to be highly susceptible to aminoglycosides (e.g., amikacin) and to carbapenems (e.g., imipenem). The findings of this study should inform efforts aimed at addressing the AMR challenge and may prove useful in guiding small animal clinicians in the state of Indiana in choosing appropriate antimicrobials for empiric therapy.

# 351 Acknowledgments

We thank the Integrative Data Science Initiative at Purdue University for funding this work and the Indiana Animal Disease Diagnostic Laboratory for providing the data used in these analyses.

### 355 **References**

356	1.	Paitan Y. Current Trends in Antimicrobial Resistance of Escherichia coli. Curr Top
357		Microbiol Immunol. 2018;416: 181–211. doi:10.1007/82_2018_110
358	2.	Courtice R, Sniatynski M, Rubin JE. Characterization of antimicrobial-resistant Escherichia
359		coli causing urinary tract infections in dogs: Passive surveillance in Saskatchewan, Canada
360		2014 to 2018. Journal of Veterinary Internal Medicine. 2021;35: 1389–1396.
361		doi:10.1111/jvim.16103
362	3.	LeCuyer TE, Byrne BA, Daniels JB, Diaz-Campos DV, Hammac GK, Miller CB, et al.
363		Population Structure and Antimicrobial Resistance of Canine Uropathogenic Escherichia
364		coli. J Clin Microbiol. 2018;56: e00788-18. doi:10.1128/JCM.00788-18
365	4.	Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the
366		United States, 2019. Centers for Disease Control and Prevention (U.S.); 2019 Nov.
367		doi:10.15620/cdc:82532
368	5.	Pomba C, Rantala M, Greko C, Baptiste KE, Catry B, van Duijkeren E, et al. Public health
369		risk of antimicrobial resistance transfer from companion animals. J Antimicrob Chemother.
370		2017;72: 957–968. doi:10.1093/jac/dkw481
371	6.	Jim ER, Mark GP. Veterinary Pharmacology and Therapeutics. 9th ed. Ames, Iowa: Wiley-
372		Blackwell, 2009.
373	7.	WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance and World
374		Health Organization - 2017 - Critically important antimicrobials for human medi.pdf.
375		Available from: https://apps.who.int/iris/bitstream/handle/10665/255027/9789241512220-
376		eng.pdf?sequence=1&isAllowed=y
376		eng.pdf?sequence=1&isAllowed=y

	niology. 1st ed. In: Giguère	pidemiology	Resistance and Its E	Antimicrobial	White DG.	Boerlin P.	8.	377
--	------------------------------	-------------	----------------------	---------------	-----------	------------	----	-----

- 378 S, Prescott JF, Dowling PM, editors. Antimicrobial Therapy in Veterinary Medicine. 1st ed.
- 379 Wiley; 2013. pp. 21–40. doi:10.1002/9781118675014.ch3
- 380 9. Wallis LJ, Szabó D, Erdélyi-Belle B, Kubinyi E. Demographic Change Across the Lifespan
- of Pet Dogs and Their Impact on Health Status. Front Vet Sci. 2018;5.
- 382 doi:10.3389/fvets.2018.00200
- 10. Conner JG, Smith J, Erol E, Locke S, Phillips E, Carter CN, et al. Temporal trends and
- predictors of antimicrobial resistance among *Staphylococcus spp.* isolated from canine
- specimens submitted to a diagnostic laboratory. PLoS One. 2018;13: e0200719.
- 386 doi:10.1371/journal.pone.0200719
- 11. Breed Standards | United Kennel Club (UKC). [cited 28 Jan 2021]. Available:
- 388 https://www.ukcdogs.com/breed-standards
- 389 12. Sweeney MT, Lubbers BV, Schwarz S, Watts JL. Applying definitions for multidrug
- resistance, extensive drug resistance and pandrug resistance to clinically significant
- livestock and companion animal bacterial pathogens. J Antimicrob Chemother. 2018;73:
- 392 1460–1463. doi:10.1093/jac/dky043
- 13. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al.
- 394 Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an
- international expert proposal for interim standard definitions for acquired resistance. Clin
- 396 Microbiol Infect. 2012;18: 268–281. doi:10.1111/j.1469-0691.2011.03570.x

- M39-A4: Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data;
  Approved Guideline—Fourth Edition. : 102.
- 15. Thungrat K, Price SB, Carpenter DM, Boothe DM. Antimicrobial susceptibility patterns of
- 400 clinical *Escherichia coli* isolates from dogs and cats in the United States: January 2008
- 401 through January 2013. Veterinary Microbiology. 2015;179: 287–295.
- 402 doi:10.1016/j.vetmic.2015.06.012
- 403 16. Shea A, McCarthy R, Lindenmayer J. Therapeutic Antibiotic Use Patterns in Dogs:
- 404 Observations from a Veterinary Teaching Hospital. J Small Anim Pract. 2011;52: 310–318.
- 405 doi:10.1111/j.1748-5827.2011.01072.x
- 406 17. Awosile BB, McClure JT, Saab ME, Heider LC. Antimicrobial resistance in bacteria
  407 isolated from cats and dogs from the Atlantic Provinces, Canada from 1994-2013. Can Vet
  408 J. 2018;59: 885–893.
- 18. Belmar-Liberato R, Gonzalez-Canga A, Tamame-Martin P, Escribano-Salazar M.
- 410 Amoxicillin and amoxicillin-clavulanic acid resistance in veterinary medicine–the situation
- 411 in Europe: a review. Veterinarni Medicina. 2011;56: 473.
- 412 19. Cummings KJ, Aprea VA, Altier C. Antimicrobial resistance trends among canine
- 413 *Escherichia coli* isolates obtained from clinical samples in the northeastern USA, 2004-
- 414 2011. Can Vet J. 2015;56: 393–398.
- 20. Boothe D, Smaha T, Carpenter DM, Shaheen B, Hatchcock T. Antimicrobial Resistance
  and Pharmacodynamics of Canine and Feline Pathogenic *E. coli* in the United States.

417	Journal of t	he American	Animal Ho	ospital As	sociation.	2012:48:37	9-389.

- 418 doi:10.5326/JAAHA-MS-5805
- 419 21. De Graef EM, Decostere A, Devriese LA, Haesebrouck F. Antibiotic resistance among
- 420 fecal indicator bacteria from healthy individually owned and kennel dogs. Microb Drug
- 421 Resist. 2004;10: 65–69. doi:10.1089/107662904323047826
- 422 22. Nyirabahizi E, Tyson GH, Dessai U, Zhao S, Kabera C, Crarey E, et al. Evaluation of
- 423 *Escherichia coli* as an indicator for antimicrobial resistance in *Salmonella* recovered from
- the same food or animal ceca samples. Food Control. 2020;115: 107280.
- 425 doi:10.1016/j.foodcont.2020.107280
- 426 23. Joosten P, Ceccarelli D, Odent E, Sarrazin S, Graveland H, Van Gompel L, et al.
- 427 Antimicrobial Usage and Resistance in Companion Animals: A Cross-Sectional Study in
- 428 Three European Countries. Antibiotics. 2020;9: 87. doi:10.3390/antibiotics9020087
- 429 24. Smith A, Wayne AS, Fellman CL, Rosenbaum MH. Usage patterns of carbapenem
- antimicrobials in dogs and cats at a veterinary tertiary care hospital. J Vet Intern Med.

431 2019/05/22 ed. 2019;33: 1677–1685. doi:10.1111/jvim.15522


432 25. Angus JC, Jang SS, Hirsh DC. Microbiological study of transtracheal aspirates from dogs
433 with suspected lower respiratory tract disease: 264 cases (1989-1995). J Am Vet Med
434 Assoc. 1997;210: 55–58.

435 26. Oluoch AO, Kim CH, Weisiger RM, Koo HY, Siegel AM, Campbell KL, et al. Nonenteric

436 *Escherichia coli* isolates from dogs: 674 cases (1990-1998). J Am Vet Med Assoc.

437 2001;218: 381–384. doi:10.2460/javma.2001.218.381

438	27.	Saputra S, Jordan D, Mitchell T, Wong HS, Abraham RJ, Kidsley A, et al. Antimicrobial
439		resistance in clinical Escherichia coli isolated from companion animals in Australia.
440		Veterinary Microbiology. 2017;211: 43-50. doi:10.1016/j.vetmic.2017.09.014
441	28.	Schmidt VM, Pinchbeck G, McIntyre KM, Nuttall T, McEwan N, Dawson S, et al. Routine
442		antibiotic therapy in dogs increases the detection of antimicrobial-resistant faecal
443		Escherichia coli. Journal of Antimicrobial Chemotherapy. 2018;73: 3305-3316.
444		doi:10.1093/jac/dky352
445	29.	Wedley AL, Dawson S, Maddox TW, Coyne KP, Pinchbeck GL, Clegg P, et al. Carriage of
446		antimicrobial resistant Escherichia coli in dogs: Prevalence, associated risk factors and
447		molecular characteristics. Veterinary Microbiology. 2017;199: 23-30.
448		doi:10.1016/j.vetmic.2016.11.017
449	30.	Papich MG. Antibiotic Treatment of Resistant Infections in Small Animals. Veterinary
450		Clinics of North America: Small Animal Practice. 2013;43: 1091–1107.
451		doi:10.1016/j.cvsm.2013.04.006
452	31.	Boothe DM, Debavalya N. Impact of Routine Antimicrobial Therapy on Canine fecal
453		Escherichia coli Antimicrobial Resistance: A Pilot Study. International Journal of Applied
454		Research inVeterinary Medicine. 2011;9: 11.
455	32.	Ball KR, Rubin JE, Chirino-Trejo M, Dowling PM. Antimicrobial resistance and
456		prevalence of canine uropathogens at the Western College of Veterinary Medicine
457		Veterinary Teaching Hospital, 2002-2007. Can Vet J. 2008;49: 985–990.
458		



# Figure 1